Loading...
Loading...
XBIT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 10.4M |
| Operating I/L | -10.9M |
| Other Income/Expense | 0.9M |
| Interest Income | 2.7M |
| Pretax | -10.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.0M |
XBiotech Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of True Human monoclonal antibodies for the treatment of inflammatory and infectious diseases. The company's product pipeline includes interleukin-1 alpha therapies targeting conditions such as cancer, stroke, heart attack, and arthritis, as well as True Human COVID-19 therapy for the treatment of the COVID-19 mutant virus. By focusing on the development of innovative therapies, XBiotech Inc. generates revenue through the sale and licensing of its proprietary antibody-based treatments for various medical conditions.
